The Howard Gilman Institute for Valvular Heart Disease
blank top line
home
heart valve disease
patient care
about the institute
research
conference
in the news
contact us
contact us

Research

IN THIS SECTION

1. Overview

2. Research Focus

3. Projects

4. Publications

 

Publications

Books

Borer JS, Isom OW (Editors and authors).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II. Advances in Cardiology, 2004: 41: 1-190, Karger (Basel).

Borer, JS, Contemporary Diagnosis and Management of Valvular Heart Diseases, Handbooks in Health Care, Newtown PA (2003), 277 pp.

Borer JS, Isom OW (Eds.).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II, Advances in Cardiology, 2002; 39:1-217, Karger (Basel).

Borer JS, Somberg J. (eds and authors) Cardiovascular Drug Development, Marcel Dekker, (New York), 1999.

Journal Articles & Book Chapters

2009

Brophy J, Mukherjee D, Crofford LJ, Peura DA, Lincoff DM, Nissen SE for the PRECISION Investigators. Rationale, design, and governance of PRECISION, a cardiovascular endpoint trial of non-steroidal anti-inflammatory agents (NSAIDS) in patients with arthritis. American Heart Journal 2009, in press.

Truter SL, Catanzaro DF, Borer JS, Lee E, Gupta A, Supino PG,  Carter J, Herrold EM, Huang Z, Pitlor LL, Dumlao TF. Extracellular matrix remodeling in aortic regurgitation: role of mitogen-activated protein kinases. Cardiology 2009, in press.

McFarlane SI, Borer JS. Inhibition of the renin angiotesin system and prevention of diabetes and cardiovascular disease: mechanistic insights and lessons learned from clinical trials. Current Diabetes Reports 2009; in press.

Cohn J, Cleland JGF, Lubsen J, Borer JS, Teg PG, Perelman M, Zannad F. Unconventional endpoints in cardiovascular clinical trials: should we be moving away from morbidity and mortality? Journal of Cardiac Failure 2009; in press.

Borer JS. Management decisions in aortic regurgitation: has the time for exercise assessment finally arrived? Journal of the American College of Cardiology: Imaging 2009; in press.

Hennekens CH, DeMets D, Bairey-Merz N, Borzak S, Borer JS. Doing more good than harm:  need for a cease fire. American Journal of Medicine 2009; in press.

Sasson L, Ureche A, Manolache G, Ciubotaru A, Borer JS, Schachner A. Nitric oxide synthase inhibitor (MTR-105) during open heart surgery: a double blind placebo controlled study of hemodynamic effect and safety. Cardiology 2009, in press.

Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter JN, Herrold EM, Dumlao TF, Borer, JS. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts. Cardiology 2009;113:161-168 (DOI: 10.1159/000187723) 

Borer JS. Ischemic mitral regurgitation: the 2007 H.J.C. Swan Memorial Prize in Medical Writing – an editorial. Cardiology 2009;112:243 (DOI: 10.1159/000151692) 

Supino PG, Borer JS, Franciosa JA, Preibisz JJ, Hochreiter CA, Krieger KH, Girardi LN, Bouraad D, Forur L. Acceptability and psychometric properties of the Minnesota Living With Heart Failure questionnaire among patients undergoing heart valve surgery: validation and comparison with SF-36. Journal of Cardiac Failure, 2009, in press.

2008

Borer JS. Heart rate: from risk marker to risk factor. European Heart Journal Supplements 2008;10:Supplement F:F2-F6.

Borer JS, Gordon DJ, Geller NL, Zannad F. When should data and safety monitoring committees share interim results? Journal of the American Medical Association 2008;299:1710-1712.

Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Yu F, Southard E, Lee LY,  Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites. American Journal of Therapeutics 2008; in press.

Borer JS, Girardi LN. Repair of the congenitally bicuspid regurgitant aortic valve – a strategic advance. J Am Coll Cardiol 2008;52:50-51.

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials. Cardiology 2008;110:73-80.

Borer JS, LeHeuzey Y. Characterization of the heart rate lowering action of ivabradine, a selective If current inhibitor. American Journal of Therapeutics, 2008, in press.

2007

Borer JS, Supino PG. Radionuclide angiography part ii: equilibrium imaging in Nuclear Cardiac Imaging: Principles and Applications, 4th Edition (Iskandrian A, ed), Oxford, New York, 2007, in press

Borer JS (Guest Editor). If inhibition by ivabradine. Drugs 2007; Supplement 2:1-49. (Borer JS. Forward, pp1-2). 

DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs 2007;67 (Suppl 2):15-24.

Borer JS. If inhibition in challenging cardiac conditions: evidence and future prospects. Medicographia 2007; 29:295-300.

Borer JS. Cellular and molecular basis of myocardial dysfunction in valvular heart diseases: implications for therapeutic decisions. Hjerteforum 2007, in press.

Borer JS. Heart rate and ischemic heart disease, in Heart Rate Management (Benetos A, ed), Wolters Kluwer Health (Paris), 2007, pp. 71-84.

Borer JS. Angiotensin converting enzyme (ACE) inhibition: a landmark advance in treatment for cardiovascular diseases. European Heart Journal 2007; Supplements 9;Suppl E: E2-E9.

Supino PG, Borer JS. Teaching clinical research methodology to the academic medical community: a fifteen-year retrospective of a comprehensive curriculum. Medical Teacher 2007; 29:346-352.

Supino PG, Borer JS, Herrold EM, Hochreiter CA, Preibisz J, Schuleri K, Roman MJ, Kligfield P. Prognostic impact of systolic hypertension on asymptomatic patients with chronic severe aortic regurgitation and initial normal left ventricular performance at rest. American Journal of Cardiology 2005; 96:964-970.

Borer JS. Indications for operation for aortic regurgitation in asymptomatic patients in Harrison’s Online (Harrison’s Principles of Internal Medicine on line updates, Cardiovascular Disease) (Braunwald E, ed), McGraw-Hill (New York), 2007 (5/4/07), (www.accessmedicine.com), pp. 1-7.

Truter SL, Catanzaro DF, Borer JS, Lee E, Gupta A, Supino PG, Carter J, Herrold EM, Huang Z, Pitlor LL, Dumlao TF. Extracellular matrix remodeling in aortic regurgitation: role of mitogen-activated protein kinases. JACC, in review 2007

Borer JS, Supino PG. Radionuclide angiography. Equilibrium imaging in Nuclear Cardiac Imaging: Principles and Applications, 4th Edition (Iskandrian A, Garcia, EV eds), Oxford University Press, New York, 2007, pp. 515 – 540 (in press).

Friedewald V, Bonow RO, Borer JS, Carabello BA, Kleine P, Akins C, Roberts WC The Editor’s roundtable: cardiac valve surgery. American Journal of Cardiology 2007; 99:1269-1278.

Supino PG, Borer JS. A new course on hypothesis and protocol development. Medical Education 2007; 41:525-526.

Borer JS, Herrold EM, Carter JN, Catanzaro DF, Supino P. Cellular and molecular basis of remodelling in valvular heart diseases. Heart Failure Clinics 2006; 2: 415-424.

Supino PG, Borer JS, Schuleri K, Gupta A, Hochreiter C, Kligfield P, Herrold EM, Preibisz J, Bomsztyk M. Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation. American Journal of Cardiology 2007; 100:1274-1281

Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Lipicky RJ, Pfeffer MA, Pitt B, Zannad F. Assessment of cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart Journal 2007;28:1904-1909.

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Similarities and Differences in Design Considerations for Cell Therapy and Pharmacologic Cardiovascular Clinical Trials. Cardiology 2007, in press.

Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Yu F, Southard E, Lee LY, Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites.Circulation Research 2007, in review.

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez-Sendon JL, Steg PG, Tardif J-C, Tavazzi L, Tendera M. Resting heart rate: a forgotten factor in cardiovascular disease? Journal of the American College of Cardiology 2007, 50:823-830.

White WB, West CR, Borer JS, Gorelick PS, Lavange LM, Pan SX, Weiner E, Verburg K.Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. American Journal of Cardiology 2007, 99:91-98.

Sasson L, Ureche A, Manolache G, Ciubotaru A, Borer JS, Schachner A. Nitric oxide synthase inhibitor (MTR-105) during open heart surgery: a double blind placebo controlled study of hemodynamic effect and safety. Chest, 2007, in review.

2006

Supino PG, Borer JS. Epidemiology of valvular heart diseases: a growing public health problem. Heart Failure Clinics 2006; 2:379-393.

Fox KM, Ferrari R, Yusuf S, Borer, JS. Should ACE inhibitors be used to improve outcome in patients with coronary disease and preserved LV function? European Heart Journal 2006; 27:2154-2157.

Borer JS. Therapeutic effects of If blockade: evidence and perspective. Pharmacological Research 2006; 53:440-446.

Corbett JR, Akinboboye OO, Bacharach SL, Borer JS, Botvinick EH, DePuey EG, Ficaro EP, Hansen CL, Henzlova MJ, Van Kriekinge S. Equilibrium radionulide angiocardiography. Journal of Nuclear Cardiology 2006; 13:e56-79.

Borer JS. Can Ifinhibition help in angina? Dialogues in Cardiovascular Medicine 2006; 11:21-29.

Borer JS. Cyclo-oxygenase inhibition: what should we do to resolve the confusion? An American Perspective. Journal of Cardiovascular Pharmacology, 2006; 47(Suppl. 1):S87-S91.

Borer JS. Clinical effect of “pure” heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine. Advances in Cardiology, 2006, 43:54-64.

Borer JS. Valvular heart disease, in Principles and Practice of Geriatric Medicine (Pathy MSJ, Morley JE, Sinclair S, eds), 4th Edition, Wiley (Chichester), 2006; 529-540. .

Gupta A, Carter J, Truter SL, Leer EH, Herrold EM, Borer JS. Cellular response of human cardiac fibroblasts to mechanically simulated aortic regurgitation. American Journal of Therapeutics 2006;13:8-11.

Borer JS, Truter SL, Supino PG, Herrold EM, Carter JN, Hochreiter CA, Heaphy J. Molecular and cellular pathophysiology: basis for pharmacological therapy in regurgitant valvular diseases? in Advances in Heart Disease: New Trends in Research, Diagnosis and Treatment (Kimchi A, ed), Medimond (Bologna) 2006, pp. 599-602.

Borer JS, Schuleri K. Myocardial remodeling: physiological and pathological, in Myocardial Remodeling: Mechanisms and Treatment (Greenberg B, ed), Taylor and Francis (New York), 2006; pp. 121-138.

< Prev

 

 

blank